Exelixis Inc. (EXEL)

22.65
NASDAQ : Health Technology
Prev Close 22.82
Day Low/High 22.23 / 23.03
52 Wk Low/High 13.42 / 31.79
Avg Volume 4.20M
Exchange NASDAQ
Shares Outstanding 298.98M
Market Cap 6.82B
EPS 0.50
P/E Ratio 19.50
Div & Yield N.A. (N.A)

Latest News

My 2 Top Stock Picks for 2019

My 2 Top Stock Picks for 2019

It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.

Exelixis' Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets For The Treatment Of Hypertension In Japan

Exelixis' Collaborator Daiichi Sankyo Receives Regulatory Approval For MINNEBRO™ (Esaxerenone) Tablets For The Treatment Of Hypertension In Japan

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Daiichi Sankyo Company, Limited ("Daiichi Sankyo") received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for esaxerenone tablets, MINNEBRO™ 1.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DNR, EXEL, GIL, HF, ITGR, TEF Downgrades: CERC, FSB, PED, QTNA Initiations: URGN Read on to get TheStreet Quant Ratings' detailed report:

3 Profitable Small Biotech Names to Consider

3 Profitable Small Biotech Names to Consider

Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.

Exelixis And Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) Of Cabozantinib In Combination With Atezolizumab Versus Sorafenib In Previously Untreated Advanced Hepatocellular Carcinoma

Exelixis And Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) Of Cabozantinib In Combination With Atezolizumab Versus Sorafenib In Previously Untreated Advanced Hepatocellular Carcinoma

Exelixis, Inc. (Nasdaq:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today announced the initiation of COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX ®) in combination with atezolizumab (TECENTRIQ ®) versus sorafenib in previously untreated...

Exelixis Announces Webcasts Of Investor Conference Presentations In November

Exelixis Announces Webcasts Of Investor Conference Presentations In November

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Here's a Handful of Ways to Navigate Biotech's Choppy Seas

Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.

Here's How I'm Playing Biotech Now

Here's How I'm Playing Biotech Now

I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.

Exelixis' Partner Ipsen Receives European Commission Approval For CABOMETYX® (cabozantinib) Tablets For The Treatment Of Hepatocellular Carcinoma In Adults Previously Treated With Sorafenib

Exelixis' Partner Ipsen Receives European Commission Approval For CABOMETYX® (cabozantinib) Tablets For The Treatment Of Hepatocellular Carcinoma In Adults Previously Treated With Sorafenib

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX ® (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated...

Exelixis To Present At The Stifel 2018 Healthcare Conference On November 13, 2018

Exelixis To Present At The Stifel 2018 Healthcare Conference On November 13, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Small Biotechs Finally Join in Market Rebound

Small Biotechs Finally Join in Market Rebound

Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.

Exelixis Announces Third Quarter 2018 Financial Results And Provides Corporate Update

Exelixis Announces Third Quarter 2018 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2018 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Noteworthy Monday Option Activity: EXEL, CONN, EBS

Noteworthy Monday Option Activity: EXEL, CONN, EBS

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Exelixis Inc , where a total volume of 22,454 contracts has been traded thus far today, a contract volume which is representative of approximately 2.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 66.7% of EXEL's average daily trading volume over the past month, of 3.4 million shares.

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Tech Doesn't Have Good Defense: Cramer's 'Mad Money' Recap (Thursday 9/6/18)

Jim Cramer, celebrating the opening of the NFL season, says this is just another day of total tech mayhem.

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

United Parcel Service, TJX Companies: 'Mad Money' Lightning Round

Jim Cramer takes a look at United Parcel Service, TJX Companies, Anheuser-Busch InBev, Fiat Chrysler, AbbVie, Nvidia, Excelixis, Bank of America, Endo Pharmaceutical and more.

Exelixis Announces Results From The Dose-Escalation Stage Of The Phase 1b COSMIC-021 Study Of Cabozantinib In Combination With Atezolizumab In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis Announces Results From The Dose-Escalation Stage Of The Phase 1b COSMIC-021 Study Of Cabozantinib In Combination With Atezolizumab In Previously Untreated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced results from the dose-escalation stage of the phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in previously untreated advanced renal cell carcinoma (RCC).

Exelixis Announces Results From Two Analyses Evaluating Effect Of PD-L1 Expression Or Prior Treatment With Checkpoint Inhibitors On Efficacy Of Cabozantinib In Patients With Advanced Renal Cell Carcinoma

Exelixis Announces Results From Two Analyses Evaluating Effect Of PD-L1 Expression Or Prior Treatment With Checkpoint Inhibitors On Efficacy Of Cabozantinib In Patients With Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced results from two analyses evaluating the effect of PD-L1 expression or prior treatment with immune checkpoint inhibitors on the efficacy of cabozantinib in patients with advanced renal cell carcinoma (RCC).

Exelixis To Release Third Quarter 2018 Financial Results On Thursday, November 1, 2018

Exelixis To Release Third Quarter 2018 Financial Results On Thursday, November 1, 2018

Exelixis, Inc. (NASDAQ: EXEL) announced today that its third quarter 2018 financial results will be released on Thursday, November 1, 2018 after the markets close.

Cabozantinib To Be Featured In 13 Presentations At ESMO 2018 Congress

Cabozantinib To Be Featured In 13 Presentations At ESMO 2018 Congress

Exelixis, Inc. (NASDAQ:EXEL) today announced that data from clinical trials of cabozantinib will be the subject of 13 presentations at the European Society for Medical Oncology (ESMO) 2018 Congress, which is being held October 19-23, 2018 in Munich,...

Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) Of Cabozantinib In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy

Exelixis Initiates Phase 3 Pivotal Trial (COSMIC-311) Of Cabozantinib In Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior VEGFR-Targeted Therapy

Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of a phase 3 pivotal trial (COSMIC-311) of single-agent cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer (DTC) who have progressed after up to two prior...

3 Small Biotech Stocks to Watch in the Fourth Quarter

3 Small Biotech Stocks to Watch in the Fourth Quarter

These are just a few of the names I expect to do well to close out 2018.

3 Small Biotechs on My Q4 Watch List

3 Small Biotechs on My Q4 Watch List

These are a few of the names I expect to do well to close out 2018.

Exelixis Larger Than S&P 500 Component Stericycle

Exelixis Larger Than S&P 500 Component Stericycle

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Exelixis Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Stericycle Inc. , according to The Online Investor.

Exelixis To Present At The Cantor Fitzgerald Global Healthcare Conference On October 2, 2018

Exelixis To Present At The Cantor Fitzgerald Global Healthcare Conference On October 2, 2018

Exelixis, Inc. (NASDAQ: EXEL) today announced that Michael M.

Exelixis' Partner Ipsen Announces Positive CHMP Opinion For CABOMETYX® (cabozantinib) Tablets For Previously Treated Hepatocellular Carcinoma

Exelixis' Partner Ipsen Announces Positive CHMP Opinion For CABOMETYX® (cabozantinib) Tablets For Previously Treated Hepatocellular Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX ® (cabozantinib)...

Synchrony, Exelixis Look Like Good Values

Synchrony, Exelixis Look Like Good Values

The credit card provider and the biotech concern appear cheap relative to their potential.

Exelixis' Partner Ipsen Announces Health Canada's Approval Of CABOMETYX® (cabozantinib) Tablets For The Treatment Of Adults With Previously Treated Advanced Renal Cell Carcinoma

Exelixis' Partner Ipsen Announces Health Canada's Approval Of CABOMETYX® (cabozantinib) Tablets For The Treatment Of Adults With Previously Treated Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc.

TheStreet Quant Rating: B- (Buy)